Quince Therapeutics Inc (QNCX)

Currency in USD
16.750
-1.440(-7.92%)
Closed·
16.690-0.060(-0.36%)
·
Advertisement
QNCX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.10018.030
52 wk Range
3.660909.980
Key Statistics
Prev. Close
16.75
Open
18
Day's Range
15.1-18.03
52 wk Range
3.66-909.98
Volume
103.56K
Average Volume (3m)
231.86K
1-Year Change
-94.7656%
Book Value / Share
56.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QNCX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
86.667
Upside
+417.41%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Quince Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 86.667
(+417.41% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy4.00-76.12%-Maintain25/06/2026
Leerink
Buy4.00-76.12%-New Coverage24/06/2026
Cantor Fitzgerald
Buy4.00-76.12%-New Coverage23/06/2026
Maxim Group
Hold---Downgrade30/01/2026
Lucid Capital Markets
Sell--8.00Downgrade30/01/2026

Earnings

Latest Release
19/05/2026
EPS / Forecast
76.90 / -3.12
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare QNCX to Peers and Sector

Metrics to compare
QNCX
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.4x−0.4x
PEG Ratio
−0.01−0.090.00
Price/Book
1.0x3.8x2.6x
Price / LTM Sales
-17.5x3.0x
Upside (Analyst Target)
377.6%104.4%51.3%
Fair Value Upside
Unlock4.5%7.3%Unlock

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
155.32K0.95%2.60M
Other Institutional Investors
2.60M15.93%43.49M
Public Companies & Retail Investors
13.55M83.12%226.95M
Total
16.3M100.00%273.04M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Millennium Management LLC8.61%1,403,69723,512
Woodline Partners LP3.19%520,0008,710

People Also Watch

1.850
OCG
+6.32%
12.3600
SPCB
+8.04%
1.0800
ONCO
-4.42%
1.1900
ABTS
+2.59%
1.300
EZGO
-0.76%

FAQ

What Is the Quince Therapeutics (NASDAQ: QNCX) Share Price Today?

The Quince Therapeutics stock price today is 16.750 USD.

What Stock Exchange Does Quince Therapeutics (QNCX) Trade On?

Quince Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Quince Therapeutics?

The stock symbol (also called a 'ticker') for Quince Therapeutics is "QNCX."

What Is the Current Quince Therapeutics Market Capitalisation?

As of today, Quince Therapeutics (NASDAQ: QNCX) market cap is 16.380M USD.

What Is Quince Therapeutics's (QNCX) Earnings Per Share (TTM)?

The Quince Therapeutics EPS is currently -116.790 (Trailing Twelve Months).

When Is the Next Quince Therapeutics Earnings Date?

Quince Therapeutics's next earnings report will be released on 11/08/2026.

Is QNCX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Quince Therapeutics moving averages and other technical indicators, the daily buy/sell signal for QNCX stock is Strong Sell.

How Many Times Has Quince Therapeutics Stock Split?

Quince Therapeutics has split 2 times. (See the QNCX stock split history page for full effective split date and price information.)

How Many Employees Does Quince Therapeutics Have?

Quince Therapeutics has 38 employees, based on their latest Companies House report.

What is the current trading status of Quince Therapeutics (NASDAQ: QNCX)?

As of 02/07/2026, Quince Therapeutics (QNCX) is trading at a share price of 16.750 USD, with a previous close of 16.750 USD. The stock has fluctuated within a day range of 15.100 USD to 18.030 USD, while its 52-week range spans from 3.660 USD to 909.980 USD.

What Is Quince Therapeutics (QNCX) Price Target According to Analysts?

The average 12-month price target for Quince Therapeutics is 86.667 USD, with a high estimate of 100 USD and a low estimate of 80 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +417.41% Upside potential.

What Is the QNCX After Hours Price?

QNCX's last after hours stock price is 16.690 USD, the stock has decreased by -0.060, or -0.360%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.